BACKGROUND: Estimates of the lifetime probability of acquiring human papillomavirus (HPV) can help to quantify HPV incidence, illustrate how common HPV infection is, and highlight the importance of HPV vaccination. METHODS: We developed a simple model, based primarily on the distribution of lifetime numbers of sex partners across the population and the per-partnership probability of acquiring HPV, to estimate the lifetime probability of acquiring HPV in the United States in the time frame before HPV vaccine availability. RESULTS: We estimated the average lifetime probability of acquiring HPV among those with at least 1 opposite sex partner to be 84.6% (range, 53.6%-95.0%) for women and 91.3% (range, 69.5%-97.7%) for men. Under base case assumptions, more than 80% of women and men acquire HPV by age 45 years. CONCLUSIONS: Our results are consistent with estimates in the existing literature suggesting a high lifetime probability of HPV acquisition and are supported by cohort studies showing high cumulative HPV incidence over a relatively short period, such as 3 to 5 years.
BACKGROUND: Estimates of the lifetime probability of acquiring human papillomavirus (HPV) can help to quantify HPV incidence, illustrate how common HPV infection is, and highlight the importance of HPV vaccination. METHODS: We developed a simple model, based primarily on the distribution of lifetime numbers of sex partners across the population and the per-partnership probability of acquiring HPV, to estimate the lifetime probability of acquiring HPV in the United States in the time frame before HPV vaccine availability. RESULTS: We estimated the average lifetime probability of acquiring HPV among those with at least 1 opposite sex partner to be 84.6% (range, 53.6%-95.0%) for women and 91.3% (range, 69.5%-97.7%) for men. Under base case assumptions, more than 80% of women and men acquire HPV by age 45 years. CONCLUSIONS: Our results are consistent with estimates in the existing literature suggesting a high lifetime probability of HPV acquisition and are supported by cohort studies showing high cumulative HPV incidence over a relatively short period, such as 3 to 5 years.
Authors: K E Tipirneni; E L Rosenthal; L S Moore; A D Haskins; N Udayakumar; A H Jani; W R Carroll; A B Morlandt; M Bogyo; J Rao; Jason M Warram Journal: Mol Imaging Biol Date: 2017-10 Impact factor: 3.488
Authors: Manika Suryadevara; Cynthia A Bonville; Donald A Cibula; Joseph B Domachowske Journal: Hum Vaccin Immunother Date: 2020-10-16 Impact factor: 3.452
Authors: Rayleen M Lewis; Lauri E Markowitz; Julia W Gargano; Martin Steinau; Elizabeth R Unger Journal: J Infect Dis Date: 2018-03-05 Impact factor: 5.226